FDA Will Soon Finalize Obesity Guidance, May Tackle CV Safety Separately
This article was originally published in The Pink Sheet Daily
Executive Summary
In wake of rimonabant, formal evaluation of depression will probably be needed for centrally acting drugs.
You may also be interested in...
‘Weight Management’ Guidance Changes From FDA Could Tip Scales In Obesity Reimbursement Debate
Expected revision to the 2007 draft might more clearly communicate that obesity is a disease than the earlier guidance, and could provide advice on getting indications for treating complications. If US FDA embraces the new thinking, it could help build the case for Medicare reimbursement.
Eric Colman, FDA’s Lead Obesity Drug Reviewer, Dies At Age 53
As a reviewer, team leader and deputy director in the Division of Metabolism and Endocrinology Products, Colman spearheaded the agency’s policy development on weight-management products.
The Inevitable Outcome: Diabetes Safety Model Expands To Weight Loss…And Beyond?
The cardiovascular outcomes standard used for diabetes drugs since 2008 is moving to weight loss. That is important in itself, but also for what it says about the lessons FDA has taken from the diabetes experience – and what it might mean about regulatory expectations for other chronic drug classes in the future.